Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor monotherapy versus aspirin plus ticagrelor after PCI in high bleeding risk patients
ChiCTR1900025949Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor and aspirin in coronary arteriosclerosis (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Clinical hemorrhagic events. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900025949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025949.